Reason for request
Inclusion
No clinical benefit demonstrated in dual therapy with metformin or in triple therapy with metformin/sulfonylurea or metformin/insulin in the management of type 2 diabetic patients inadequately controlled with metformin, or with a combination of metformin and a sulfonylurea or metformin and insulin
No clinical benefit in monotherapy or in dual therapy with a sulfonylurea or insulin
- JARDIANCE has Marketing Authorisation in the treatment of type 2 diabetes in monotherapy and in combination with other blood glucose-lowering medicinal products, including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
- The available clinical data are based mainly on studies versus placebo, whereas active comparators do exist. Just one study has shown modest efficacy for JARDIANCE 25 mg/day versus glimepiride (sulfonylurea) 1-4 mg/day whereas its maximum dose is 6 mg/day.
Clinical Benefit
| Moderate |
Monotherapy : Insufficient for reimbursement by National Health Insurance
Dual therapy :
- with metformin : Moderate
Tritherapy :
- with metformin and a sulfonylurea : Moderate
- with insulin and metformin : Moderate |
| Insufficient |
- with a sulfonylurea : Insufficient for reimbursement by National Health Insurance
- with insulin : Insufficient for reimbursement by National Health Insurance |
Clinical Added Value
| no clinical added value |
In the indications as dual therapy with metformin, and as tritherapy with metformin and a sulfonylurea or with metformin and insulin :
In light of the available clinical data, namely placebo-controlled studies with empagliflozin 10 or 25 mg/day when active comparators are available and modest
results from a sequential non-inferiority and superiority study of empagliflozin at its maximum dose of 25 mg/day versus an active comparator, the sulfonylurea glimepiride, at doses of 1 to 4 mg/day (whereas its maximum dose is 6 mg/day), the Committee considers that the JARDIANCE proprietary medicinal products do not provide any improvement in actual benefit (level V, non-existent) in the management of patients with poorly controlled type 2 diabetes, as dual oral therapy in combination with metformin and as tritherapy in combination with metformin and a sulfonylurea or with metformin and insulin.
In the indications as monotherapy, and as dual therapy with sulfonylureas or insulin : Not applicable. |
| Not applicable |
|
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
Yy6AA58YgjdYLAVc
